While markedly increased circulatory levels of ACE2 activity after native rACE2 administration are capable of effectively lowering blood pressure in models of Ang II-induced hypertension [6,7,14] or renin overexpression in the circulation [15], their use is not suitable for treatment of other forms of kidney disease. This evidence concerns the gene AGT and kidney disorder.